Gelteq Limited (GELS)
GELS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GELS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | 2024 |
| SEC CIK | 0001920092 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials
No annual revenue in SEC XBRL data for this filer.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As discussed in Note 4 to the consolidated financial statements, the Company has an excess of current liabilities over current assets and suffered net loss from operations, which raises substantial doubt about its ability to continue as a going concern." | 20-F 2025-11-17 |
| Cash and burn | not enough data | None on EDGAR |
| Shares outstanding | No cover-page share count in XBRL | None on EDGAR |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | M&K CPAS, PLLC, The Woodlands, Texas, United States | PCAOB Form AP 2025-11-24 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-11-02 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-06-30 | Not filed | -$6.6M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2025-11-17 |
| FY 2024 2024-06-30 | Not filed | -$3.5M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2025-11-17 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2025-08-29 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-11-16 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-07-06 |
Source: SEC EDGAR submissions feed, 73 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.6% |
| 1 month | -20.8% |
| 3 months | -34.6% |
| Year to date | -52.5% |
| 1 year | -62.4% |
| From 52-week high | -75.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
| AZTR | Azitra Inc | $0.6270 | +3.06% | $3.8M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.54 | -3.75% | $3.8M |
| TRAW | Traws Pharma Inc. | $0.2600 | +3.59% | $4.0M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier